Co-Diagnostics, Inc. To Host Booth At 10Th Gene Quantification Event In Munich, Germany, March 20-22

(MENAFN- PR Newswire) Chair of Company's SAB, Dr. Carl Wittwer, to present on at-home PCR testing

SALT LAKE CITY, March 17, 2023 /PRNewswire/ --
Co-Diagnostics, Inc.
(Nasdaq: codx ) (the 'Company' or 'Co-Dx'), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 10th Gene Quantification Event held March 20-24 at the Technical University of Munich. Dr. Carl Wittwer, Chair of the Company's Scientific Advisory Board (SAB) will also be presenting at the event.

Dr. Wittwer's presentation, titled 'At-Home PCR Testing for SARS-CoV-2,' will take place at 2:00 pm local time on March 20 in Lecture Hall 15, and is expected to discuss how the Company's upcoming Co-Dx PCR HomeTM* testing platform makes at-home testing for infectious disease diagnosis feasible, including the multiplexing capabilities of the device. Co-Dx recently announced the initiation of clinical evaluations for this at-home/POCT real-time PCR platform, which is subject to FDA review and is not currently for sale.

The focus topics for this year's Gene Quantification Event include SARS-CoV-2, liquid biopsy and CNA, multi-omics biomarkers and more, with an Industrial Exhibition presenting the latest molecular diagnostics, qPCR, digital-PCR and NGS services to an international audience. To learn more about the event, including in-person and virtual registration details, please visit .

Attendees interested in learning more about the Company and its products, including its upcoming Co-Dx PCR Home platform, are invited to visit Booth 7 in the Industrial Exhibition.

*The Co-Dx PCR Home platform is subject to U.S. Food and Drug Administration ('FDA') review and has not been cleared or approved for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR HomeTM platform and to locate genetic markers for use in applications other than infectious disease.

SOURCE Co-Diagnostics


PR Newswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.